Literature DB >> 17616707

Elevated frequencies of self-reactive CD8+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope.

Korosh Kianizad1, Laura A Marshall, Natalie Grinshtein, Dannie Bernard, Renate Margl, Sheng Cheng, Friedrich Beermann, Yonghong Wan, Jonathan Bramson.   

Abstract

Immunization of mice with human dopachrome tautomerase (hDCT) provides greater protection against melanoma than immunization with the murine homologue (mDCT). We mapped the CD8(+) and CD4(+) T-cell epitopes in both proteins to better understand the mechanisms of the enhanced protection. The dominant CD8(+) T-cell epitopes were fully conserved between both proteins, yet immunization with hDCT produced frequencies of CD8(+) T cells that were 5- to 10-fold higher than immunization with mDCT. This difference was not intrinsic to the two proteins because comparable frequencies of CD8(+) T cells were elicited by both antigens in DCT-deficient mice. Strikingly, only hDCT elicited a significant level of specific CD4(+) T cells in wild-type (WT) mice. The murine protein was not devoid of CD4(+) T-cell epitopes because immunization of DCT-deficient mice with mDCT resulted in robust CD4(+) T-cell immunity directed against two epitopes that were not identified in WT mice. These results suggested that the reduced immunogenicity of mDCT in WT mice may be a function of insufficient CD4(+) T-cell help. To address this possibility, the dominant CD4(+) T-cell epitope from hDCT was introduced into mDCT. Immunization with the mutated mDCT evoked CD8(+) T-cell frequencies and protective immunity comparable with hDCT. These results reveal a novel mechanism by which xenoantigens overcome tolerance. Our data also suggest that immunologic tolerance is more stringent for CD4(+) T cells than CD8(+) T cells, providing a mechanism of peripheral tolerance where autoreactive CD8(+) T cells fail to be activated due to a lack of autoreactive CD4(+) T cells specific for the same antigen.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616707     DOI: 10.1158/0008-5472.CAN-06-4336

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Authors:  Dannie Bernard; Michael S Ventresca; Laura A Marshall; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.

Authors:  Ying Zhang; Hildegund C J Ertl
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

3.  Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.

Authors:  Luigi Aurisicchio; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Rita Mancini; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

4.  Potentiating cancer immunotherapy using an oncolytic virus.

Authors:  Byram W Bridle; Kyle B Stephenson; Jeanette E Boudreau; Sandeep Koshy; Natasha Kazdhan; Eleanor Pullenayegum; Jérôme Brunellière; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

5.  Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy.

Authors:  Adam E Snook; Michael S Magee; Stephanie Schulz; Scott A Waldman
Journal:  Eur J Immunol       Date:  2014-05-21       Impact factor: 5.532

6.  Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Authors:  Byram W Bridle; Jeanette E Boudreau; Brian D Lichty; Jérôme Brunellière; Kyle Stephenson; Sandeep Koshy; Jonathan L Bramson; Yonghong Wan
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

7.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

8.  DNA vaccines encoding altered peptide ligands for SSX2 enhance epitope-specific CD8+ T-cell immune responses.

Authors:  Heath A Smith; Brian T Rekoske; Douglas G McNeel
Journal:  Vaccine       Date:  2014-01-31       Impact factor: 3.641

9.  Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

Authors:  Wolfgang W Leitner; Matthew C Baker; Thomas L Berenberg; Michael C Lu; P Josef Yannie; Mark C Udey
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

10.  Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.

Authors:  A J Robert McGray; Dannie Bernard; Robin Hallett; Ryan Kelly; Mayank Jha; Caitlin Gregory; Jennifer D Bassett; John A Hassell; Guillaume Pare; Yonghong Wan; Jonathan L Bramson
Journal:  Oncoimmunology       Date:  2012-07-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.